| 2.66 -0.35 (-11.63%) | 06-23 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.8 |
1-year : | 4.38 |
| Resists | First : | 3.25 |
Second : | 3.75 |
| Pivot price | 3.14 |
|||
| Supports | First : | 2.45 |
Second : | 2.03 |
| MAs | MA(5) : | 2.94 |
MA(20) : | 3.19 |
| MA(100) : | 4.2 |
MA(250) : | 19.68 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 11.7  |
D(3) : | 9 |
| RSI | RSI(14): 33.4 |
|||
| 52-week | High : | 66.5 | Low : | 2.45 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BDRX ] has closed below the lower bollinger band by 1.9%. Bollinger Bands are 59.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 111 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.95 - 2.97 | 2.97 - 2.99 |
| Low: | 2.42 - 2.43 | 2.43 - 2.45 |
| Close: | 2.63 - 2.66 | 2.66 - 2.69 |
Biodexa Pharmaceuticals Plc, a biopharmaceutical company in the clinical development stage, is dedicated to advancing a diverse portfolio of products. Founded in 2000 and headquartered in Cardiff, United Kingdom, the company was formerly known as Midatech Pharma plc until its rebranding in March 2023. Its research and development efforts are focused on addressing significant unmet medical needs, including familial adenomatous polyposis, non-muscle invasive bladder cancer, Type 1 diabetes, and a spectrum of rare or orphan brain cancers. The company's primary drug candidate, Tolimidone, a selective activator of the lyn kinase enzyme, is currently undergoing Phase II clinical trials for the management of Type 1 diabetes. Additionally, Biodexa is progressing MTX110 through Phase I studies as an investigational treatment targeting specific challenging brain malignancies such as diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma. Beyond its direct drug pipeline, Biodexa Pharmaceuticals also provides a suite of advanced drug delivery platforms designed to optimize therapeutic efficacy. These include Q-Sphera, a microtechnology utilizing polymer microspheres for controlled, sustained release of medications; MidaSolve, an oligosaccharide nanotechnology that facilitates the solubilization of drugs, enabling their direct and localized administration into tumor sites; and MidaCore, which employs gold nanoparticles for precise targeting of diseased areas, allowing for the delivery of either chemotherapeutic or immunotherapeutic agents. The company has established strategic collaboration agreements with pharmaceutical industry leaders Janssen and Melior.
Thu, 18 Jun 2026
Biodexa Pharmaceuticals PLC - TradingKey
Thu, 18 Jun 2026
Biodexa Pharmaceuticals PLC (BDRX) Institutional Confidence - TradingKey
Thu, 18 Jun 2026
Biodexa Pharmaceuticals PLC (BDRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Wed, 17 Jun 2026
[6-K] Biodexa Pharmaceuticals Plc Current Report (Foreign Issuer) | BDRX SEC Filing - Form 6-K - Stock Titan
Wed, 17 Jun 2026
Biodexa delays annual meeting to June 30 after quorum failure - Stock Titan
Wed, 17 Jun 2026
Postponement and Re-scheduling of Annual General Meeting - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 1 (M) |
| Shares Float | 26,420 (M) |
| Held by Insiders | 0.9 (%) |
| Held by Institutions | 52.2 (%) |
| Shares Short | 13 (K) |
| Shares Short P.Month | 20 (K) |
| EPS | -26.72 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 24.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.1 % |
| Return on Equity (ttm) | -61.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -5.86 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -10.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -11 (M) |
| Levered Free Cash Flow | -9 (M) |
| PE Ratio | -0.1 |
| PEG Ratio | 0 |
| Price to Book value | 0.1 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|